Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director · President and CEO | September 21, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date September 21, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 11,160 |
Reported balance
After 2026-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-21 · Sale · Disposed 87 · Balance 11,160 F1: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. F2: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
F2: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-30 · Disposition to issuer · Disposed 150,190 · Balance 61,813 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 61,813 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-30 · Disposition to issuer · Disposed 165,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-30 · Disposition to issuer · Disposed 82,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-30 · Disposition to issuer · Disposed 131,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-30 · Disposition to issuer · Disposed 168,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-30 · Disposition to issuer · Disposed 138,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2018 Filed Dec 18, 2018 19:49 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 138,000 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001562180-18-005030 · primarydocument.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 138,000 shares Expires 2028-12-16 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:49 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 23,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005030 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2022-12-20 F3 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 11,453 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003131 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,453 shares Expires 2018-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: RSUs representing 11,453 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 5,038 | $18.50 | $93,203.00 |
DisclosureSEC source: 0001562180-18-003131 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,693 F2 · kind: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 11,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003131 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001803 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 6,875 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 6,118 | $16.32 | $99,845.76 |
DisclosureSEC source: 0001562180-18-001803 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,278 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001803 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes (i) 6,875 unvested Restricted Stock Units ("RSUs") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 6,875 shares of common stock issued upon the vesting of these RSU's on April 1, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 168,000 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0001562180-17-003956 · primarydocument.xml · derivative · entry 5 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2027-12-16 F7 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 28,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003956 · primarydocument.xml · derivative · entry 4 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2021-12-17 F6 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 5,468 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003956 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,407 Underlying: Common Stock · 5,468 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vested on December 16, 2017. F5 · balance_after: Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 2,548 | $10.92 | $27,824.16 |
DisclosureSEC source: 0001562180-17-003956 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,521 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003956 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes 13,750 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001465 · primarydocument.xml · derivative · entry 3 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 6,875 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017. F5 · balance_after: Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 4,535 | $8.94 | $40,542.90 |
DisclosureSEC source: 0001562180-17-001465 · primarydocument.xml · nonDerivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,526 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001465 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 2,152 shares were withheld upon vesting to satisfy tax withholding obligations.The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F2 · balance_after: Includes 13,750 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and 2,332 shares purchased pursuant to the issuer's Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
| April 01, 2017 Filed Apr 6, 2017 20:31 UTC Amendment | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 6,543 | $8.94 | $58,494.42 |
DisclosureSEC source: 0001562180-17-001486 · primarydocument.xml · nonDerivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,851 F1 · shares: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. The ending balance has also been corrected to include 2,332 shares purchased pursuant to the issuer's Employee Stock Purchase Plan on December 31, 2016. No other information in such form 4 is being amended. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:53 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 131,250 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001562180-16-003919 · primarydocument.xml · derivative · entry 2 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2026-12-27 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2017. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:53 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 21,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003919 · primarydocument.xml · derivative · entry 1 Saccomano Nicholas A · CIK 0001609284 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 21,875 shares Expires 2020-12-28 F1 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.